Literature DB >> 8722639

The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.

K Murakami-Mori1, T Taga, T Kishimoto, S Nakamura.   

Abstract

Kaposi's sarcoma (KS) is most frequently associated with HIV-infected individuals (AIDS-KS). While AIDS-KS-derived spindle cells (AIDS-KS cells) contribute to the development of KS lesions, growth regulation of these cells in vivo is poorly understood. AIDS-KS cells express considerable amounts of the signal transducing subunit (gp130) of the IL-6 receptor, but only a scanty amount of its binding subunit (IL-6R alpha). This phenotype can account for the lack of IL-6 responsiveness of AIDS-KS cells. We now report that the soluble form of IL-6R alpha (sIL-6R alpha), lacking transmembrane and cytoplasmic regions, functions as a potent growth factor for AIDS-KS cells by making these cells responsive to IL-6. After exposure to sIL-6R alpha together with IL-6 in culture, AIDS-KS cells assumed a spindle-shaped morphology and showed a remarkable augmentation of growth, while IL-6 alone did not induce AIDS-KS cell growth. Even without the addition of IL-6, sIL-6R alpha induced significant growth levels of AIDS-KS cells. Since AIDS-KS cells express high levels of IL-6, it is likely that, in the presence of sIL-6R alpha, these cells acquire an IL-6 autocrine growth loop. Anti-gp130 antibodies blocked the action of sIL-6R alpha on AIDS-KS cells; hence, we refer to sIL-6R alpha as a gp130-related AIDS-KS cell growth factor. In contrast, the soluble form of gp130 (sgp130) had inhibitory effects on AIDS-KS cell growth, thereby suggesting that a complex regulatory system is involved in the modulation of the gp130-mediated AIDS-KS cell growth. In recent years, soluble forms of IL-6R alpha and gp130 have been detected in the sera of healthy individuals and increased levels of sIL-6R alpha as well as IL-6 have been noted in the sera of HIV-infected patients. It seems reasonable to assume that perturbed production of sIL-6R alpha and sgp130 may play a crucial role in the development and regression of AIDS-KS lesions by directly acting on growth of KS cells through the gp130-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722639     DOI: 10.1093/intimm/8.4.595

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

1.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

2.  Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.

Authors:  Hirofumi Nakanishi; Kiyoko Yoshioka; Susumu Joyama; Nobuhito Araki; Akira Myoui; Shingo Ishiguro; Takafumi Ueda; Hideki Yoshikawa; Kazuyuki Itoh
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  A candidate gene approach for virally induced cancer with application to HIV-related Kaposi's sarcoma.

Authors:  Brahim Aissani; Howard W Wiener; Kui Zhang; Richard A Kaslow; Kisani M Ogwaro; Sadeep Shrestha; Lisa P Jacobson
Journal:  Int J Cancer       Date:  2013-07-27       Impact factor: 7.396

Review 4.  Recent Advances in the Role of Arid5a in Immune Diseases and Cancer.

Authors:  Kishan Kumar Nyati; Tadamitsu Kishimoto
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

5.  C-reactive protein: a physiological activator of interleukin 6 receptor shedding.

Authors:  S A Jones; D Novick; S Horiuchi; N Yamamoto; A J Szalai; G M Fuller
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.